Weekly Signal: 41 | Evidence Tightens Across Neurotechnology

Table of Contents

• Weekly Signal

• Complete our community challenge

• Refer a Neurohacker

• Help us Improve

🧠 Weekly Signal

Neurotechnology News | Jan 10–Jan 16, 2026

Let's cut through the noise this week!

This week, we saw a large randomized trial challenge a widely discussed brain-stimulation approach for attention-deficit/hyperactivity disorder (ADHD) and a new sensor design aimed at closed-loop neuromodulation. Industry momentum showed up in a $250M+ brain–computer interface (BCI) seed round and fresh funding for deep brain stimulation (DBS) stroke rehab. Meanwhile, FDA cleared an at-home neuromodulation path for depression. Bottom line: clinical evidence and commercialization signals are tightening standards.

🧠 SCIENCE & CLINICAL TRIALS

🟢 Trigeminal nerve stimulation fails ADHD trial

Published: Jan 16, 2026
Read more ➡️ University of Southampton / Nature

In a multicenter, double-blind randomized controlled trial (n=150), external trigeminal nerve stimulation did not outperform sham on ADHD outcomes despite good tolerability. The result narrows the evidence for noninvasive neurostimulation in pediatric ADHD and may influence clinical decision-making and coverage.

💡 Big Picture: Negative trials are signal—neuromodulation needs stronger endpoints and clearer responder profiles.

🟢 Organic “event-based” sensors for closed-loop stimulation

Published: Jan 15, 2026
Read more ➡️ Nature (beginner friendly) / Nature

Researchers report an organic electrochemical “event-based” sensor designed to detect neural signals with lower energy demands than rigid silicon approaches. The work targets a key bottleneck for closed-loop systems—fast sensing under tight power constraints—though it remains a validated prototype, not a clinical device.

💡 Big Picture: Better sensing hardware is foundational for safer, longer-lasting closed-loop neurotherapies.

💼 INDUSTRY & STARTUPS

🟢 Merge Labs raises ~$252M for noninvasive BCI

Published: Jan 15, 2026
Read more ➡️ Tech Crunch / OpenAi

Merge Labs surfaced with a reported ~$250M seed round; OpenAI confirmed participation and framed the effort around brain–computer interfaces and neural-data modeling. The technical direction emphasizes noninvasive approaches; near-term deliverables and clinical timelines remain unspecified.

💡 Big Picture: Big capital + foundation-model ambitions could accelerate BCI tooling—but the proof will be safety data and measurable bandwidth gains.

🟢 Australia’s NRFC invests $20M in connectomics

Published: Jan 16, 2026
Read more ➡️Business News Australia / NRFC 

Australia’s National Reconstruction Fund Corporation (NRFC) took a $20M preferred equity stake in Omniscient Neurotechnology to support expansion of its clinical brain-mapping platform. The announcement positions connectomics software as a scaling clinical workflow, not just research infrastructure.

💡 Big Picture: Public capital is now underwriting neuroimaging analytics scale—adoption will hinge on integration, evidence, and reimbursement.

🟢 Enspire raises $10.3M for DBS stroke rehabilitation

Published: Jan 13, 2026
Read more ➡️ Pulse 2.0 / PR Newswire

Enspire DBS Therapy announced $10.3M to advance its RESTORE pivotal study combining deep brain stimulation with structured rehabilitation for chronic post-stroke arm impairment. The company said interim results are expected in mid-2027, targeting future U.S. Food and Drug Administration (FDA) marketing authorization.

💡 Big Picture: If efficacy holds, neuromodulation could expand from symptom control into rehabilitation-focused care pathways.

🏛️ POLICY & ETHICS

🟢 FDA-cleared at-home neuromodulation for depression

Published: Jan 12, 2026
Read more ➡️ Mass Device / PR Newswire

Neurolief announced FDA premarket approval (PMA) for ProlivRx, an at-home, prescription neuromodulation system for adults with major depressive disorder who did not respond adequately to at least one antidepressant. The shift from clinic-only to home use raises practical requirements for monitoring, adherence, and real-world outcome tracking.

💡 Big Picture: At-home neuromodulation will pressure health systems to standardize safety follow-up and define reimbursement-friendly care models.

🟢 New CPT code for connectomic analysis (July 2026)

Published: Jan 14, 2026
Read more ➡️ Yahoo Finance / Globe Newswire

Omniscient announced a new Current Procedural Terminology (CPT) code (1039T) for connectomic analysis workflows, effective July 1, 2026. If payers recognize and reimburse it, advanced brain-network mapping may face fewer billing barriers in routine neurosurgical planning.

💡 Big Picture: Reimbursement plumbing often decides what becomes standard of care—coding is a concrete step toward broader clinical uptake.

🎯 Community Challenge

Ready to take neurotech to the next level? Share your insights, projects, ideas, our upcoming list of NeuroHacks, or your own groundbreaking work—and watch the inspiration ripple across the community!

How to Participate

1. Follow HackTheNeuron

   Show us support by following us on X, Instagram and Tik Tok!

2. Create a Post
   Show us what you’re working on—DIY projects, research breakthroughs, or even your latest neurotech musings.

3. Use #Neurotech
   This helps your ideas reach fellow enthusiasts and potential collaborators.

4. Mention @HackTheNeuron
   Tag us directly in your post so we never miss your entry—and we’ll amplify your work across our entire NeuroCircuit community!

Why Join?

• Boost Your Reach: Tap into a niche but fast-growing community for extra visibility.

• Build Your Network: Connect with researchers, developers, and curious tinkerers who share your passion.

• Shape Neurotech’s Future: Your project or insight could spark the next big breakthrough—or inspire someone else’s.

We can’t wait to see your creativity in action! Fire up X, LinkedIn, Facebook, Instagram, or TikTok, and spread the word. Let’s spark innovation together!

🚀Recruit More Neurohackers

Your referrals are the engine that drives our community forward. Share your unique referral link with friends, colleagues, or fellow neurotech enthusiasts—and watch us grow together!

• Spread the Word: Copy your personal referral link and post it on social, forums, or in emails.

• Unlock Exclusive Perks: Every friend who subscribes through your link brings you closer to special rewards—insider insights, private Discord access, early project previews, and more.

• Be the Catalyst: The more you share, the stronger our network becomes. Help us build the ultimate neurotech hub—one referral at a time!

✍️Help Us Improve

Your input is what will make The NeuroCircuit and Hack The Neuron better. Let us know what you’d like more of—and what we can do differently.

• Share Your Ideas: Tell us which topics, features, or formats you’d love to see next.

• Spot the Gaps: Let us know if anything’s missing or unclear in our content and community tools.

• Shape the Experience: Whether it’s new challenges, tutorials, or platform features, your suggestions guide our roadmap.